Deepansh Mody1, Ahmad I M Athamneh1, Mohamed N Seleem2. 1. Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA. 2. Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA; Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, IN, USA. Electronic address: mseleem@purdue.edu.
Abstract
OBJECTIVES: The rapid emergence of hypervirulent Clostridium difficile (C. difficile) isolates and the paucity of effective anti-clostridial antibiotics call for extensive research to identify new treatment options. This study aimed to test the anti-clostridial activity of bioactive extracts of turmeric, which is a natural herb widely known for its profound medicinal properties. METHODS: The MICs of turmeric derivatives were determined against 27 C. difficile strains, including hypervirulent (BI/NAP1/027) and clinical toxigenic isolates. Additionally, their ability to inhibit C. difficile toxin production and spore formation was investigated. Furthermore, the safety profiles of turmeric derivatives regarding their effects on human gut microflora - such as Bacteroides, Lactobacillus and Bifidobacterium - were evaluated. RESULTS: Curcuminoids, the major phytoconstituents of turmeric - including curcumin, demethoxycurcumin and bisdemethoxycurcumin - inhibited growth of C. difficile at concentrations ranging from 4 to 32μg/mL. Additionally, curcuminoids showed no negative effect on major populating species of the human gut. Curcumin was more effective than fidaxomicin in inhibiting C. difficile toxin production, but less so in inhibiting spore formation. CONCLUSION: The findings suggest that curcumin has potential as an anti-clostridial agent. More work is needed to further investigate the efficacy of curcumin as a stand-alone drug or as a supplement of current drugs of choice, as it has no antagonistic activities but might overcome their drawbacks.
OBJECTIVES: The rapid emergence of hypervirulent Clostridium difficile (C. difficile) isolates and the paucity of effective anti-clostridial antibiotics call for extensive research to identify new treatment options. This study aimed to test the anti-clostridial activity of bioactive extracts of turmeric, which is a natural herb widely known for its profound medicinal properties. METHODS: The MICs of turmeric derivatives were determined against 27 C. difficile strains, including hypervirulent (BI/NAP1/027) and clinical toxigenic isolates. Additionally, their ability to inhibit C. difficile toxin production and spore formation was investigated. Furthermore, the safety profiles of turmeric derivatives regarding their effects on human gut microflora - such as Bacteroides, Lactobacillus and Bifidobacterium - were evaluated. RESULTS:Curcuminoids, the major phytoconstituents of turmeric - including curcumin, demethoxycurcumin and bisdemethoxycurcumin - inhibited growth of C. difficile at concentrations ranging from 4 to 32μg/mL. Additionally, curcuminoids showed no negative effect on major populating species of the human gut. Curcumin was more effective than fidaxomicin in inhibiting C. difficile toxin production, but less so in inhibiting spore formation. CONCLUSION: The findings suggest that curcumin has potential as an anti-clostridial agent. More work is needed to further investigate the efficacy of curcumin as a stand-alone drug or as a supplement of current drugs of choice, as it has no antagonistic activities but might overcome their drawbacks.
Authors: Richard J Vickers; Glenn Tillotson; Ellie J C Goldstein; Diane M Citron; Kevin W Garey; Mark H Wilcox Journal: Int J Antimicrob Agents Date: 2016-05-30 Impact factor: 5.283
Authors: Laith Yakob; Thomas V Riley; David L Paterson; John Marquess; Ricardo J Soares Magalhaes; Luis Furuya-Kanamori; Archie C A Clements Journal: Sci Rep Date: 2015-07-28 Impact factor: 4.379
Authors: Watcharapong Mitsuwan; Suthinee Sangkanu; Chonticha Romyasamit; Chalermpon Kaewjai; Tajudeen O Jimoh; Maria de Lourdes Pereira; Abolghasem Siyadatpanah; Sunil Kayesth; Muhammad Nawaz; Mohammed Rahmatullah; Mark S Butler; Polrat Wilairatana; Christophe Wiart; Veeranoot Nissapatorn Journal: Int J Parasitol Drugs Drug Resist Date: 2020-11-17 Impact factor: 4.077